Anthony A. McKinney
Fondateur chez Ethismos Research, Inc.
Provenance du réseau au premier degré de Anthony A. McKinney
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 18 | |
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Neurovance, Inc.
 Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA.
4
| Subsidiary | Miscellaneous Commercial Services | 4 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Novazyme Pharmaceuticals, Inc.
 Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Ethismos Research, Inc.
 Ethismos Research, Inc. BiotechnologyHealth Technology Ethismos Research, Inc. is a clinical-stage drug development company located in an undisclosed location. Ethismos is developing pharmaceutical treatments for pain, depression, and substance use disorders. Amitifadine is different from opioids and addiction treatments because it is not believed to be addictive, nor is it a stimulant or an opioid. Ethismos plans to commence phase 2 amitifadine clinical trials for opioid-sparing and facilitation of opioid taper as a non-opioid analgesic in chronic pain patients treated with long-term opioids. The American company is also exploring amitifadine trials in depression maintenance post-ketamine treatment, methamphetamine dependence, and nicotine cessation. The private company was founded by Anthony A. McKinney and he has been the CEO since incorporation. The company is continuing the development of the patented small molecule, amitifadine, a triple reuptake inhibitor, originally developed by euthymics bioscience, and acquired by ethismos in 2017.
1
| Private Company | Biotechnology | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Anthony A. McKinney via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| AMICUS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Operating Officer | |
| ALIGN TECHNOLOGY, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
| SEAGEN INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| NUVASIVE, INC. | Medical Specialties | Director/Board Member Comptroller/Controller/Auditor | |
Corthera, Inc.
 Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN. | College/University | Doctorate Degree Doctorate Degree | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Undergraduate Degree Corporate Officer/Principal | |
| University of California, Los Angeles | College/University | Graduate Degree Undergraduate Degree | |
| GI DYNAMICS, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| AIDS Vaccine Advocacy Coalition | Chairman | ||
Labrys Biologics, Inc.
 Labrys Biologics, Inc. BiotechnologyHealth Technology Labrys Biologics, Inc. provides biotechnology services. It is a venture-financed development stage biotechnology company, which focuses on treatments for chronic migraine. The company was founded by Corey S. Goodman in 2012 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
| OCERA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
| AMARIN CORPORATION PLC | Pharmaceuticals: Major | Director/Board Member | |
| Sofinnova Management VI LLC | Corporate Officer/Principal | ||
| University of Toronto | College/University | Doctorate Degree | |
Dauntless 1, Inc.
 Dauntless 1, Inc. Pharmaceuticals: MajorHealth Technology Dauntless 1, Inc. engages in pharmaceuticals. The company is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Dauntless Pharmaceuticals, Inc.
 Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Drugstore Chains | Founder | |
Aeovian Pharmaceuticals, Inc.
 Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Pharmaceuticals: Major | Director/Board Member | |
| University of Missouri-Kansas City | College/University | Doctorate Degree | |
| UIC College of Pharmacy | College/University | Undergraduate Degree | |
| Glaxo, Inc. | Chief Tech/Sci/R&D Officer | ||
| Clinical Research Foundation-America | President | ||
| POZEN INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Investment Managers | Private Equity Investor | |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Miscellaneous Commercial Services | Director/Board Member | |
| University of Kansas | College/University | Corporate Officer/Principal | |
Quanta Therapeutics, Inc.
 Quanta Therapeutics, Inc. BiotechnologyHealth Technology Quanta Therapeutics, Inc. develops biotechnologies. The American company was founded in 2018 by Cameron Pitt, Frank McCormick. Perry D. Nisen has been the CEO of the company since 2021. | Biotechnology | Director/Board Member | |
Intrepida Bio, Inc.
 Intrepida Bio, Inc. Pharmaceuticals: MajorHealth Technology Intrepida Bio, Inc. discovers and develops medicines to modulate the innate immune system to fight cancer and other diseases. The company was founded by Joel F. Martin and Olivier Laurent and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chairman | |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Pionyr Immunotherapeutics, Inc.
 Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
| Scarborough College | College/University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 47 |
| Canada | 3 |
| Irlande | 2 |
| Royaume-Uni | 2 |
Sectorielle
| Health Technology | 28 |
| Consumer Services | 11 |
| Commercial Services | 5 |
| Retail Trade | 3 |
| Non-Energy Minerals | 2 |
Opérationnelle
| Director/Board Member | 216 |
| Corporate Officer/Principal | 80 |
| Independent Dir/Board Member | 41 |
| Chairman | 33 |
| President | 32 |
Relations les plus connectées
| Insiders | |
|---|---|
| Michael Powell | 48 |
| Brian H. Dovey | 40 |
| Joseph Lacob | 35 |
| Dan Omstead | 33 |
| Dan Turner | 29 |
| Timothy Barberich | 28 |
| Louis C. Bock | 27 |
| John Crowley | 19 |
| Dennis D. Kim | 16 |
| Julie Smith | 15 |
| Graham Cooper | 14 |
| James A. Thomson | 13 |
| Gary D. Tollefson | 12 |
| Heather Turner | 10 |
| Walter Piskorski | 10 |
- Bourse
- Insiders
- Anthony A. McKinney
- Connexions Sociétés
